4MO Development and Validation of CDKPredX, a Novel Predictor of Response to Neoadjuvant Endocrine Therapy and CDK4/6 Inhibitors Versus Chemotherapy in ER+/HER2- Breast Cancer: Correlative Analysis of the Randomized Phase II PREDIX Luminal B Trial